Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

August 11, 2017: By Jon Swedien

Ocular Therapeutix logoOcular Therapeutix’ cash, cash equivalents, and marketable securities totaled $66 million at the end of Q2-2017, the Bedford, Massachusetts, company announced Aug. 8.

Cash used in operating activities was $11.3 million in Q2-2017, compared with $9.8 million in Q2-2016, Ocular Therapeutix said. Total costs and operating expenses for Q2-2017 were $18.8 million, compared with $11.5 million in Q2-2016, the company said.

Ocular Therapeutix reported a net loss of approximately $18.7 million in Q2-2017, compared with a net loss of $11.4 million in Q2-2016. The Q2-2017 results include $2.1 million in non-cash charges for stock-based compensation and depreciation, compared with $1.7 million in such non-cash charges in Q2-2016.

The company is working to obtain approval for its lead product candidate, Dextenza, a proposed treatment for pain after ophthalmic surgery.

In mid-July, Ocular Therapeutix received a complete response letter (CRL) from the US FDA for its resubmitted new drug application (NDA) for Dextenza due to deficiencies in manufacturing and testing.

It was Dextenza’s second CRL related to plant issues.

Ocular Therapeutix made $400 thousand in revenues during Q2-2017 from product sales of ReSure Sealant, a product indicated for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023